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Abstract
Mutations in the X-linked Cyclin-Dependent Kinase-Like 5 gene (CDKL5) cause early onset
infantile spasms and subsequent severe developmental delay in affected children. Deleteri-
ous mutations have been reported to occur throughout the CDKL5 coding region. Several
studies point to a complex CDKL5 gene structure in terms of exon usage and transcript
expression. Improvements in molecular diagnosis and more extensive research into the
neurobiology of CDKL5 and pathophysiology of CDKL5 disorders necessitate an updated
analysis of the gene. In this study, we have analysed human and mouse CDKL5 transcript
patterns both bioinformatically and experimentally. We have characterised the predominant
brain isoform of CDKL5, a 9.7 kb transcript comprised of 18 exons with a large 6.6 kb 3’-
untranslated region (UTR), which we name hCDKL5_1. In addition we describe new exonic
regions and a range of novel splice and UTR isoforms. This has enabled the description of
an updated gene model in both species and a standardised nomenclature system for
CDKL5 transcripts. Profiling revealed tissue- and brain development stage-specific differ-
ences in expression between transcript isoforms. These findings provide an essential back-
drop for the diagnosis of CDKL5-related disorders, for investigations into the basic biology
of this gene and its protein products, and for the rational design of gene-based and molecu-
lar therapies for these disorders.
Introduction
Mutations in the X-linked Cyclin-Dependent Kinase-Like 5 gene, CDKL5 (Mendelian Inheri-
tance in Man, MIM: 300203; previously known as STK9), cause a range of phenotypes, includ-
ing EIEE2 (MIM: 300672), a form of early infantile epileptic encephalopathy [1, 2], and
infantile spasms [3–7]. CDKL5mutations have also been described in patients diagnosed with
PLOSONE | DOI:10.1371/journal.pone.0157758 June 17, 2016 1 / 22
a11111
OPEN ACCESS
Citation: Hector RD, Dando O, Landsberger N,
Kilstrup-Nielsen C, Kind PC, Bailey MES, et al.
(2016) Characterisation of CDKL5 Transcript
Isoforms in Human and Mouse. PLoS ONE 11(6):
e0157758. doi:10.1371/journal.pone.0157758
Editor: Ruben Artero, University of Valencia, SPAIN
Received: February 8, 2016
Accepted: June 3, 2016
Published: June 17, 2016
Copyright: © 2016 Hector et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The Chief Scientist Office of the Scottish
Government (grant ETM/334) and the Rett Syndrome
Association Scotland provided funding to SRC and
MESB. NL and CKN are supported by the Italian
parents’ association L’Albero di Greta. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
West syndrome, Lennox-Gastaut syndrome and atypical forms of Rett syndrome (RTT) [4, 5].
In addition to the characteristic early-onset seizures, the phenotype may also include a number
of other features, such as stereotypic hand movements, severe psychomotor retardation and
general hypotonia [3, 5, 8–11]. Studies also report visual impairment and poor eye contact [5,
9, 10]. It is widely assumed that most CDKL5-related phenotypes result from loss of function
mutations, but putative gain-of-function mutations [12], as well as large duplication events
that include the CDKL5 gene region, have also been identified [13–15].
CDKL5 is located on the X-chromosome (Xp22.13) and is subject to X-chromosome inacti-
vation. All reported mutations thus far have dominant effects on phenotype and affected
patients are almost always heterozygous females. Hemizygous males are known, however, and
are invariably severely affected [6]. The clinical variability observed in heterozygous females
may partly be explained by variable X-inactivation ratios in the brain [16]. Incidence data are
not widely available, but, altogether, the CDKL5 disorders are becoming recognised as being
more common than hitherto appreciated.
Although the CDKL5 disorders are not congenital, the early postnatal onset of symptoms
indicates that CDKL5 plays a crucial role in brain development. CDKL5 is also expressed
within the mature adult nervous system [12], where it appears especially abundant in forebrain
neurons [17]. CDKL5 is expressed throughout the cell, including the nucleus and the cyto-
plasm of the cell soma and dendrites. Studies in cell and animal models have shown that
CDKL5 is important for neurite outgrowth and dendritic spine development as well as for
functional neuronal plasticity [18–20]. It has also been implicated as an important regulator of
cellular responses to oxidative stress [21]. Two Cdkl5 knockout (KO) mouse models have been
reported, with phenotypes including impaired motor control, altered behaviour, abnormal eye
tracking, general hypoactivity and morphological features such as reduced dendritic arborisa-
tion of cortical neurons [22, 23]. However, spontaneous seizures, a key feature of CDKL5 disor-
der in patients, are not observed in mice.
The multiple cellular locations and potential functions of CDKL5 may, in part, be explained
by its molecular heterogeneity. CDKL5 is known to exist as a number of isoforms resulting
from alternative splicing, and several transcripts have been identified; however, nothing is
known about their functional differences or developmental expression. Cdkl5 transcripts are
expressed widely throughout the body [24, 25]. All known CDKL5 isoforms appear to include
a highly conserved serine/threonine kinase domain [26] located in the N-terminal half of the
protein and a Thr-Xaa-Tyr (TEY) motif that is thought to activate other kinases, such as those
in the MAP kinase family [27, 28]. Other functional regions, such as nuclear localisation signals
(NLS) and nuclear export signals (NES), are predicted to be present within the otherwise much
more poorly characterised C-terminal half of the protein [12]. Loss-of-function mutations are
known to occur throughout the coding regions of the gene but many pathogenic missense
mutations cluster within the region encompassing the catalytic domain [17, 29].
Knowledge of gene transcript isoforms and their developmental expression profiles is essen-
tial for understanding their mechanistic roles in brain development. For example, different iso-
forms of the Syngap gene, mutations in which also lead to EIEE [30], have different
developmental expression profiles and opposing effects on synaptic function [31]. Further-
more, comparison of isoforms across species may give insight into species-specific differences
in phenotypes. Finally, knowledge of the spatio-temporal expression patterns of CDKL5 iso-
forms will provide information that is essential for the development of therapeutic avenues
such as gene and protein replacement. A number of studies have investigated CDKL5 gene
structure and transcript expression in different tissues [5, 24, 25, 32, 33] but the set of tran-
scripts and resulting protein isoforms remains incompletely characterised, and a standardised
nomenclature for these isoforms has not been instituted. The aim of this study was to
CDKL5 Transcript Isoforms in Human and Mouse
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characterise the mRNA products of human CDKL5 and mouse Cdkl5 using a combination of
bioinformatic analyses and molecular methods, and to predict the protein isoforms translated
from each transcript. The study has generated a new model of CDKL5 gene structure in both
species and defines a range of previously uncharacterised transcript isoforms with unique
developmental expression profiles. To accommodate these complexities in gene expression, we
propose a new nomenclature system for CDKL5 gene products that encompasses both the
range of transcript isoforms and the predicted suite of protein isoforms.
Materials and Methods
RNA-seq Data Analysis
The following RNA-seq datasets were analysed in this study: human brain GEO sample ID
GSM1173806 [34]; human testis GEO sample ID GSM759517 and ENCODE sample ID
ENCSR693GGB [35, 36]; mouse brain GEO sample ID’s GSM1020640, GSM1020649 and
GSM1020657 [37]; mouse testis GEO sample ID’s GSM1020648, GSM1020656 and
GSM1020665 [37]. Mapping RNA-seq reads to the human and mouse genomes was carried
out using the STAR read aligner, version 2.4.2a [38]. To generate STAR genome indices for
each species, the following command line was run in each case:
STAR --runMode genomeGenerate --genomeDir <species-index-dir>
--genomeFastaFiles <fasta-files> --sjdbGTFfile <gtf-file>
where <species-index-dir> is the directory into which the index files were written,
<fasta-files> were FASTA-formatted files containing sequences from the primary
assembly of the respective species' genome (Ensembl v80), and <gtf-file> was a GTF-for-
matted genome annotation file for the respective species (also Ensembl v80). To map a particu-
lar set of RNA-seq reads to a species' genome, the following command line was run:
STAR --genomeDir <species-index-dir> --readFilesIn <read-files-1>
<read-files-2> --outSAMstrandField intronMotif --twopassMode Basic
--outSAMtype BAM SortedByCoordinate
where <species-index-dir> was the directory into which the species' index files were
written, and <read-files-1> and <read-files-2> enumerated the FASTQ-formatted
files containing paired-end RNA-seq reads for the dataset. STAR was run in two-pass mapping
mode to give the most sensitive detection of reads mapping across novel splice junctions.
RNA-seq output images were generated using the Integrative Genomics Viewer (IGV) and
Sashimi plots [39–41].
RNA Isolation
Human total RNA isolated from a range of adult tissues, including whole brain (pooled from
4 males aged 21–29) and foetal brain (pooled from 21 spontaneously aborted male and female
embryos at 26–40 weeks gestation) was obtained from Clontech (Human Total RNAMaster
Panel II, Cat. #636643), a widely-used commercial panel sourced with ethical approval based
on consent; further approval from the local University of Glasgow ethics committee was not
required. Mouse total RNA was isolated from tissues obtained from wild-type C57BL/6 mice
using the RNeasy Lipid Tissue Kit (Qiagen), according to the manufacturer’s instructions.
Animal samples were collected in accordance with the European Communities Council Direc-
tive (86/609/EEC) and with the terms of a project license under the UK Scientific Procedures
Act (1986). The quality and quantity of isolated RNA was analysed using the RNA 6000 kit on
a 2100 Bioanalyzer (Agilent), and using a Nanodrop 1000 spectrophotometer (Thermo
Scientific).
CDKL5 Transcript Isoforms in Human and Mouse
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RT-PCR
Total RNA was reverse transcribed using Superscript III (Life Technologies), according to the
manufacturer’s protocol, in 20 μl reactions containing 200 ng of RNA template and 1 μM ran-
dom hexamers. Reactions were then incubated with 2 units of RNaseH (Life Technologies) at
37°C for 20 min. End-point PCR was performed using Maxima Hot Start Green (Thermo Sci-
entific), according to the manufacturer’s protocol, in 50 μl reactions containing 500 nM gene-
specific primers, and products visualised on agarose gels. PCR was performed under the follow-
ing cycling conditions: an initial denaturation at 95°C for 2 min, then 35 cycles of 95°C for 30 s,
58°C for 30 s and 72°C for 90 s, followed by a final extension of 72°C for 7 min. A list of primers
used in the study is provided in S1 Fig.
Quantitative RT-PCR
First-strand synthesis was performed using the qScript Flex kit (Quanta Bioscience), according
to the manufacturer’s protocol, in 20 μl reactions containing 200 ng of total RNA template and
500 nM gene-specific primer or random hexamers. SYBR Green PCR reactions were carried
out using the PerfeCTa SYBR kit (Quanta Bioscience), according to the manufacturer’s proto-
col, in 20 μl reactions using 1/20th of the first-strand synthesis reaction and 300 nM gene-spe-
cific primers. PCR was performed under the following cycling conditions on an Mx3005P
thermocycler (Agilent Technologies): an initial denaturation at 95°C for 30 s, then 40 cycles of
95°C for 10 s and 60°C for 60 s, followed by a dissociation curve. Appropriate controls were
included as recommended by the MIQE guidelines [42]. A list of primers used in the study is
provided in S1 Fig. Results were analysed using the comparative quantification analysis tools
with MxPro software (Stratagene)
Rapid Amplification of cDNA Ends (RACE)
3’-RACE was performed using the 3’-RACE System for Rapid Amplification of cDNA ends
(Life Technologies), according to the manufacturer’s protocol, in 20 μl reactions containing
200 ng of total RNA template. 5’-RACE was performed using the 5’-RACE System for Rapid
Amplification of cDNA ends, Version 2.0 (Life Technologies), according to the manufacturer’s
protocol, in 25 μl reactions containing 500 ng of total RNA template and 2.5 pmol of gene-spe-
cific primer. Primary and nested PCR reactions were performed using Platinum Taq polymer-
ase (Life Technologies), according to the manufacturer’s protocol, in 50 μl reactions containing
500 nM gene-specific primer. A list of primers used in the study is provided in S1 Fig. PCR
products were cloned using the TOPO TA Cloning Kit (Life Technologies) according to the
manufacturer’s protocol. Individual colonies were grown in L-Broth, and plasmids were puri-
fied using the PureYield Plasmid Miniprep System (Promega) and then sequenced (Source
BioScience).
Results
Human CDKL5 Transcript Isoforms
To conduct a comprehensive assessment of human CDKL5 transcripts, including the possibil-
ity of novel exons and splicing events, human tissue-specific RNA-seq datasets were analysed
to identify all, including very rare, CDKL5 splicing events. Using sensitive alignment tools to
detect reads mapping across all potential splice junctions we detected 27 discrete exons. In
addition to confirming the locations of previously identified exon boundaries, we identified
novel exons and cryptic splice sites (summarised in Fig 1). The positions of all exon boundaries
and splice junctions were validated experimentally by sequencing RT-PCR products spanning
CDKL5 Transcript Isoforms in Human and Mouse
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multiple exons, and the composition of each specific isoform detected was investigated using
isoform-specific RT-PCR assays (design details are given in S1 Fig). The combined RNA-seq
and RT-PCR data demonstrated the existence of five major transcript isoforms containing dis-
tinct coding regions (with respect to protein coding), which we have termed hCDKL5_1 to
hCDKL5_5 (Fig 1; see nomenclature recommendations section below). Transcript composi-
tion, exon boundaries and chromosomal sequence coordinates are detailed in Table 1.
RT-PCR was carried out to assess transcript expression across a range of tissues (Fig 2).
hCDKL5_1 is the most abundant isoform expressed within the central nervous system (CNS)
and was detected in all adult tissues tested, appearing especially abundant in CNS, kidney, tes-
tis, prostate gland, thymus and thyroid gland (Fig 2, S2 Fig). This isoform encodes the same
protein as the CDKL5107 transcript reported previously [25]. hCDKL5_2 is identical to
hCDKL5_1 but also includes exon 17 (previously called 16a or 16b; refs. [33] and [32] respec-
tively), generating a coding sequence 123 bases (41 a.a.) larger than that of hCDKL5_1.
hCDKL5_3 and hCDKL5_4 are identical to hCDKL5_1 and hCDKL5_2, respectively, but lack
51 bases of coding sequence from the 3’ end of exon 11 due to utilisation of a cryptic splice
donor site (S3 Fig). The predicted protein made from these transcripts is 17 a.a. shorter than
hCDKL5_1, or hCDKL5_2, respectively. hCDKL5_2, hCDKL5_3 and hCDKL5_4 are also
widely expressed but appear to be of somewhat lower abundance than hCDKL5_1. Analysis of
read count data in RNA-seq datasets estimates that transcripts incorporating exon 17
(hCDKL5_2 and hCDKL5_4) constitute approximately 10% of CDKL5 transcripts expressed in
whole brain, while those using the alternative splice site in exon 11 (hCDKL5_3 and
hCDKL5_4) constitute less than 5% of transcripts in brain (S3 Fig). These observations are sup-
ported by semi-quantitative RT-PCR data (Fig 2). In contrast to the first four isoforms,
hCDKL5_5 (previously known as CDKL5115) was only detected in testis amongst the adult tis-
sues tested. These differences in relative abundance are consistent with a previous report [25].
hCDKL5_5 differs from the other transcripts at the 3’ end by splicing from a cryptic splice site
Fig 1. HumanCDKL5 gene and transcript isoforms. Diagram depicting the structure of the human CDKL5 gene and the exon composition of the five
different coding isoforms (hCDKL5_1 to hCDKL5_5). Lines linking exons indicate splicing events. Asterisks next to exon numbers indicate where
differences are found between different transcript isoforms. Dotted lines within exons indicate alternative splice sites. Introns and the 3’-UTR portion of
exon 19 are not drawn to scale.
doi:10.1371/journal.pone.0157758.g001
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Table 1. Summary of hCDKL5 transcript isoforms.
Human
X-chromosome
coordinates
CDKL5 isoform
Exon Size (bp) Exon start Exon end 1 2 3 4 5
1 88 18425608 18425695 + + + + +
1a# 333 18426069 18426401 +
1b# 229 18426691 18426919 +
44 18426876 18426919 +
1c 38 18442224 18442261 +
1d 49 18442375 18442423 +
1cd#$ 200 18442224 18442423 +
1e# 121 18443839 18443959 + +
141 18443819 18443959 +
2 226 18506935 18507160 + + + + + + + + + + +
3 35 18510820 18510854 + + + + + + + + + + +
4 46 18564477 18564522 + + + + + + + + + + +
5 137 18575354 18575490 + + + + + + + + + + +
6 121 18579848 18579968 + + + + + + + + + + +
7 60 18581891 18581950 + + + + + + + + + + +
8 91 18584263 18584353 + + + + + + + + + + +
9 190 18587954 18588143 + + + + + + + + + + +
10 81 18595348 18595428 + + + + + + + + + + +
11# 152 18598462 18598613 + + + + + + + + +
101 18598462 18598562 + +
12 967 18603902 18604868 + + + + + + + + + + +
13 102 18608811 18608912 + + + + + + + + + + +
14 106 18609465 18609570 + + + + + + + + + + +
15 124 18613152 18613275 + + + + + + + + + + +
16 100 18619867 18619966 + + + + + + + + + + +
17 123 18623879 18624001 + +
18 120 18625128 18625247 + + + + + + + + + + +
19# 217 18628371 18628587 + + +
7025 18628371 18635395 + + + + + + + +
10037 18628371 18638408 +XL +XL +XL +XL +XL +XL +XL +XL
20 84 18646007 18646090 + + +
21 183 18650410 18650592 + + +
22# 199 18653432 18653630 + + +
# novel exon, splice site or UTR, not previously characterised
$ exon 1cd represents a readthrough of exon 1c to the end of exon 1d
Exon numbers, sizes and co-ordinates for the human CDKL5 gene (GRCh38/hg38 assembly). Exon composition of each transcript isoform is indicated.
Starting coordinates for the main TSS of each initial exon are italicised; coordinates of polyadenylation sites in each terminal exon are underlined. Bold
indicate exons that contain multiple splice sites. Note that isoform hCDKL5_1 is labelled as having sub-isoforms beginning at each of the alternative ﬁrst
exons, 1a, 1b and 1e; this is also expected to be true for isoforms hCDKL5_2, _3 and _4. A subscripted ‘XL’ symbol signiﬁes usage of a more distal
polyadenylation signal and consequently the presence of an extended 3’-UTR.
doi:10.1371/journal.pone.0157758.t001
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in the newly-named exon 19 to exons 20, 21 and 22 (see Fig 1 and nomenclature section
below). We found no evidence for other transcript variants utilising exons 20–22.
Analysis of the 5’ region of the gene from RNA-seq and 5’-Rapid Amplification of cDNA
Ends (5’-RACE) data revealed multiple transcription start sites (TSSs) (Fig 3A). This indicates
the use of five separate initial exons and, thus, promoters. These five initial exons are spaced
over an 18 kb region upstream of exon 2. An analysis of potential CDKL5 open reading frames
(ORFs) predicts that all of these different 5’ ends would utilise the same ATG start codon in
exon 2, and therefore the different TSSs reflect differences in 5’-untranslated region (UTR)
composition only (Fig 3A). Exons 1, 1a and 1b are used in isoforms with notable expression in
the adult brain, whereas exons 1c and 1d are used by isoforms expressed in the adult testis. The
TSS of Exon 1a was inferred from RNA-seq data and confirmed using a specific RT-PCR assay
(Fig 3A; this TSS could not be detected by 5’-RACE, possibly due to unusual RNA secondary
structure close to the 5’ end). Exon 1e was found to be present in all five major isoforms
(hCDKL5_1 –hCDKL5_5) but was never used in combination with exons 1, 1a or 1b. Alterna-
tive splicing and read-through events (such as from exon 1c to 1d in some isoforms) result in a
complex set of CDKL5 5’-UTRs, described in Fig 3A and Table 1. Only a small number of
RNA-seq reads map to exons 1a and 1b in the brain, suggesting that these represent lower
abundance isoforms (Fig 3A). Although no RNA-seq reads mapped to exon 1e in the brain
sample analysed, RT-PCR and 5’-RACE data confirmed that transcripts initiating from this
exon were indeed present in the brain (not shown).
CDKL5 transcript 3’-UTRs have never been characterised in detail before. Previous north-
ern blot data [24] had suggested that some CDKL5 transcripts may be extremely large, poten-
tially bigger than 10 kb. Here, we analysed 3’-UTRs using RNA-seq datasets and 3’-RACE to
search for potential polyadenylation sites within the predicted UTR regions encoded by exons
19 and 22. We identified two separate canonical polyadenylation signals (AATAAA) in exon
19 used in the hCDKL5_1, _2, _3 and _4 transcripts (Fig 3B). These two signals, located 6.6 kb
and 9.7 kb downstream of the stop codon, are predicted to give rise to transcripts of approxi-
mately 9.7 and 12.8 kb, respectively. Our RT-PCR analysis indicates that both these long 3’-
UTRs are used by each of the hCDKL5_1, _2, _3 and _4 transcripts (data not shown). In the
case of the hCDKL5_5 transcript, the composition of the C-terminal region of the protein and
the sequence of the 3’-UTR is entirely different to that of the other isoforms. 3’-RACE identi-
fied a non-canonical polyadenylation signal (AATTAA) used by this isoform downstream of
the stop codon in exon 22 (Fig 3B), giving rise to a 3’-UTR of 86 bases for this isoform.
Fig 2. CDKL5 isoform expression in human tissues.RT-PCR analysis of CDKL5 isoforms in a panel of
adult tissues. β-Actin was used as a loading control.
doi:10.1371/journal.pone.0157758.g002
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Fig 3. RNA-seq and 5’- and 3’-RACEmapping of humanCDKL5 transcripts. (A) Upper panels: RNA-seq data from
brain (red) and testis (blue) datasets show reads mapping to the 5’ end of CDKL5 (the y-axis indicates read count across
the analysed region). Indicative numbers of RNA-seq reads spanning each exon junction are also shown, indicated by
values and dotted lines joining exon boundaries. Middle panels: boxes representing each exon at the 5’ end of the gene
are shown, aligned with those in the upper panels. Transcription Start Sites (TSSs) and splice events upstream of exon 2
CDKL5 Transcript Isoforms in Human and Mouse
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Mouse Cdkl5 Transcript Isoforms
To complement the new analysis of human CDKL5, a detailed analysis of mouse Cdkl5 tran-
scripts was also carried out (summarised in Fig 4). Mouse tissue-specific RNA-seq datasets
were analysed using the same methods described above to identify all potential Cdkl5 splicing
events, confirming the existence of previously identified exon boundaries and suggesting the
use of novel exons (Fig 4). RT-PCR assays were carried out and all products sequenced to
experimentally validate the presence of these splice events in Cdkl5 transcripts (S1B Fig). Alto-
gether, a total of 23 exons were identified, three of which have not been previously character-
ised, exons 1a, 20 and 21. Exon boundaries and chromosomal sequence coordinates are
detailed in Table 2. Combined, the data demonstrate the existence of five major transcript iso-
forms containing distinct coding regions (Fig 4). We have termed the first two isoforms
mCdkl5_1 andmCdkl5_2 as they are orthologous to human isoforms _1 and _2, respectively.
In contrast, the coding regions of the other three transcripts do not show full orthology to
human isoforms and are hence termedmCdkl5_6,mCdkl5_7 andmCdkl5_8 (Fig 4).
New RT-PCR assays capable of differentiating between Cdkl5 transcript isoforms were
developed and used to assess transcript expression across a range of tissues (Fig 5).mCdkl5_1
is completely orthologous to its human counterpart and also appears to be the most abundant
isoform expressed within the mouse brain. It was also detected in a variety of other adult
are indicated. Coding regions are indicated by cyan colouring and 5’-UTRs by black colouring. Lower panel: exonic
sequences for each first exon are shown. TSSs, confirmed by sequencing of 5’-RACE products, are indicated by boxes;
the major TSS is indicated by a solid box, minor TSSs are indicated by hatched boxes. (B) Upper panels: RNA-seq data
from brain and testis datasets show reads mapping to the 3’ end of CDKL5; exon boundary-spanning read counts are also
shown, as in (A), above. Middle panels: the exon composition and splicing patterns at the 3’ end of each human isoform is
indicated, colouring as in (A) above. Lower panel: sequences around each of the three polyadenylation signals and sites
(pA) are shown; each was confirmed by 3’-RACEmapping.
doi:10.1371/journal.pone.0157758.g003
Fig 4. MouseCdkl5 gene and transcript isoforms.Diagram depicting the structure of the mouseCdkl5 gene and the exon composition of the five
different coding isoforms (mCDKL5_1, _2, _6, _7, _8). Lines linking exons indicate splicing events. Asterisks next to exon numbers indicate where
differences are found between different transcript isoforms. Dotted lines within exons indicate alternative splice sites. Introns and the 3’-UTR portion of
exon 19 are not drawn to scale.
doi:10.1371/journal.pone.0157758.g004
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tissues, in agreement with a previous study [25]. We also confirm thatmCdkl5_2 is completely
orthologous to its human counterpart. The levels ofmCdkl5_2 expression in the brain appear
to be approximately 10% of that ofmCdkl5_1, according to our analysis of read counts in
RNA-seq datasets (S3 Fig). No mouse orthologues of hCDKL5_3 and hCDKL5_4 were identi-
fied. Sequence analysis of exon 11 revealed that the cryptic splice donor site is absent in mouse
due to a single nucleotide difference (S3 Fig). BLAST analysis (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) revealed that the cryptic splice site consensus sequence is present in all mammals
with Cdkl5 sequences in Genbank except mouse and a few other rodent species (not shown).
The alternative splice donor site in exon 19 is also conserved between species, and is used in
three of the mouse isoforms (mCdkl5_6, _7 and _8). Bioinformatic analysis of RNA-seq data-
sets indicated that three exons lie downstream of exon 19 (Fig 6), of which only one had previ-
ously been reported (Genbank accession: NM_001024624.2). The newly identified exons were
named exons 20 and 21, while the previously characterised exon lying approximately 15 kb
Table 2. Summary ofmCdkl5 transcript isoforms.
Mouse
X-chromosome coordinates Cdkl5 isoform
Exon Size (bp) Exon start Exon end 1 2 6 7 8
1 91 160994688 160994591 + +
1a#$ 200 160976506 160976307 + + +
2 231 160928655 160928425 + + + + +
3 35 160924486 160924452 + + + + +
4 46 160876568 160876523 + + + + +
5 137 160866053 160865917 + + + + +
6 121 160861054 160860934 + + + + +
7 60 160858859 160858800 + + + + +
8 91 160856445 160856355 + + + + +
9 190 160852330 160852141 + + + + +
10 81 160847017 160846937 + + + + +
11 152 160840446 160840295 + + + + +
12 967 160834834 160833868 + + + + +
13 102 160830022 160829921 + + + + +
14 106 160829648 160829543 + + + + +
15 124 160824098 160823975 + + + + +
16 100 160816991 160816892 + + + + +
17 123 160813050 160812928 +
18 120 160811716 160811597 + + + + +
19# 217 160808691 160808475 + + +
7065 160808691 160801627 + +
20#$ 83 160800092 160800010 +
21#$ 141 160799251 160799111 + +
22#$ 280 160784582 160784582 +
# novel exon or UTR, not previously characterised
$ mouse-speciﬁc, not orthologous to human
Exon numbers, sizes and co-ordinates for the mouse Cdkl5 gene (GRCm38/mm10 assembly). Exon composition of each transcript isoform is indicated.
Starting coordinates for the main TSS of each initial exon are italicised; coordinates of polyadenylation sites in each terminal exon are underlined. Bold
indicate exons that contain multiple splice sites.
doi:10.1371/journal.pone.0157758.t002
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downstream of exon 21 is renumbered as exon 22. Each of these three exons was confirmed by
sequencing of RT-PCR products. Exon boundaries and chromosomal sequence coordinates are
detailed in Table 2. BLAST searches revealed that none of these three exons is clearly ortholo-
gous to any conserved human or other mammalian genomic sequence downstream of the con-
served exon 19, and current evidence suggests that they are therefore specific to mouse.
Interestingly, expression ofmCdkl5_6 andmCdkl5_7, like that of hCDKL5_5, is confined to the
testis in the adult mouse, whereasmCdkl5_8 is expressed in the spleen and at very low levels in
other tissues, such as brain, heart, liver and lung, as well as in the testis (Fig 5).
5’-RACE was used to characterise the 5’ end of Cdkl5. The major TSS in brain was mapped
to position 160994677 (mm10 genomic reference sequence coordinates), indicating usage of
exon 1 by transcript isoformsmCdkl5_1 and _2 (Fig 6A). Sequencing of multiple 5’-RACE
product clones also identified other TSS’s in close proximity (Fig 6A). The 5’-UTR of these
transcripts therefore comprises approximately 260 bases. Exon 1 is well conserved between
species (sequence identity> 80%) and the sites of the major TSSs in mouse and human are
orthologous. 5’-RACE was also used to characterise the 5’ end of Cdkl5 transcripts that use the
novel, mouse-specific exon 1a. RT-PCR analysis indicated that this exon is used as an alterna-
tive first exon in isoformsmCDKL5_6,mCDKL5_7 andmCDKL5_8, which are predominantly
expressed in testis in the adult. Multiple TSSs were identified, clustered closely together at the
start of exon 1a (Fig 6A). The major TSS was mapped to position 160976506 (mm10, as
above), yielding transcripts with a 5’-UTR of 367 bases (Fig 6A).
3’-RACE analysis confirmed the existence of three alternatively-spliced transcript isoforms
that utilise exons 20–22 (Fig 6B). InmCdkl5_6 the conserved alternative splice donor site in
exon 19 splices to exon 20, then to exon 21, where it terminates (Figs 4 and 6B). InmCdkl5_7,
splicing is from the alternative splice donor site in exon 19 directly to exon 21 (Figs 4 and 6B).
BothmCdkl5_6 andmCdkl5_7 utilise the same downstream canonical polyadenylation signal,
resulting in short 168 base and 58 base 3’-UTRs, respectively (Fig 6B). However, the inclusion
of exon 20 inmCdkl5_6 results in a coding frame that terminates at a stop codon near the end
of exon 20. As splicing is detected after this exon in our 3’-RACE assay, it may be that non-
sense-mediated decay does not operate to degrade transcripts using this combination of exons.
InmCdkl5_8, splicing occurs from the alternative splice donor site in exon 19 directly to exon
22, as previously reported (Figs 4 and 6B). This transcript contains a unique, 176 bp 3’-UTR
terminating with a non-canonical polyadenylation signal (TATAAA) downstream of the stop
codon in exon 22 (Fig 6B).
Fig 5. Cdkl5 isoform expression in mouse tissues.RT-PCR analysis of Cdkl5 isoforms in a panel of adult
tissues. β-Actin was used as a loading control.
doi:10.1371/journal.pone.0157758.g005
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Fig 6. RNA-seq and 5’ and 3’-RACEmapping of mouseCdkl5 transcripts. (A) Upper panels: RNA-seq data from brain (red) and testis (blue)
datasets show reads mapping to the 5’ end of Cdkl5 (the y-axis indicates read count across the analysed region). Indicative numbers of RNA-seq
reads spanning each exon junction are also shown, indicated by values and dotted lines joining exon boundaries. Middle panels: boxes representing
each exon at the 5’ end of the gene are shown, aligned with those in the upper panels. Transcription Start Sites (TSSs) and splice events upstream of
exon 2 are indicated. Coding regions are indicated by orange colouring and 5’-UTRs by black colouring. Lower panel: exonic sequences for each first
CDKL5 Transcript Isoforms in Human and Mouse
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3’-RACE was also used to characterise the 3’-UTRs of the human-orthologous transcripts
mCdkl5_1 andmCdkl5_2. In both cases, a single canonical polyadenylation signal located 6.6
kb downstream of the stop codon in exon 19 was confirmed (Fig 6B). The signal is situated at
orthologous positions in each species, and yields transcripts of approximately 9.9 kb in the
mouse.
Nomenclature Recommendations
Based on the work described above, a new nomenclature system for human CDKL5 and mouse
Cdkl5 transcript isoforms is proposed here (Table 3). For each transcript, the gene symbol is
italicised; CDKL5 for human, Cdkl5 for mouse. This may be preceded by a letter to indicate the
species; h for human,m for mouse. This allows the naming of transcripts from other species,
such as rat, (indicated by an r), within the proposed system. The gene symbol is followed by an
underscore and a number, which will differentiate transcripts with different coding sequences.
The system is based on orthology, so the same number in different species indicates an ortholo-
gous coding sequence; for example, hCDKL5_1 comprises exonic sequences that seem to be
entirely orthologous to those found inmCdkl5_1. The proteins made from each transcript will
be named according to the same convention i.e. transcript hCDKL5_1 encodes protein isoform
hCDKL5_1.
At the 5’ end of CDKL5 isoforms expressed in the brain, most transcripts splice from exon 1
directly to exon 2 (Fig 3A). However, the identification of novel exons, TSSs and alternative
splicing in this region has shown that multiple minor transcripts display variation in their 5’-
UTRs, but not in their ORFs (Fig 3A). Additional variation is also seen at the 5’ end of
hCDKL5_5 (see Table 1 for a description of this variation). At the 3’ end, RACE mapping has
identified unique polyadenylation signals and 3’-UTRs for most transcripts utilising the differ-
ent final exons in CDKL5 and Cdkl5 (Figs 3B and 6B). However, an exception occurs with
exon are shown. TSSs, confirmed by sequencing of 5’-RACE products, are indicated by boxes; the major TSS is indicated by a solid box, minor TSSs
are indicated by hatched boxes. (B) Upper panels: RNA-seq data from brain and testis datasets show reads mapping to the 3’ end of Cdkl5; exon
boundary-spanning red counts are also shown, as in (A), above. Middle panels: the exon composition and splicing patterns at the 3’ end of each mouse
isoform is shown, colouring as in A) above. Lower panel: sequences around each of the three polyadenylation signals and sites (pA) are shown; each
was confirmed by sequencing of 3’-RACEmapping.
doi:10.1371/journal.pone.0157758.g006
Table 3. Summary ofCDKL5/Cdkl5 nomenclature.
New isoform nomenclature Coding region
sizes
Human Mouse (bp) (aa) Former name Ensembl transcript Descriptive name
hCDKL5_1 mCdkl5_1 2883 960 CDKL5107 CDKL5-005/Cdkl5-003 hCDKL5_2–19Δ17
hCDKL5_2 mCdkl5_2 3006 1001 CDKL5-16b - hCDKL5_2–19
hCDKL5_3 - 2832 943 - - hCDKL5_2-19s11Δ17
hCDKL5_4 - 2955 984 - - hCDKL5_2-19s11
hCDKL5_5 - 3093 1030 CDKL5115 CDKL5-002 hCDKL5_2–22 Δ17s19
- mCdkl5_6 2769 923 - - mCdkl5_2–21 Δ17s19
- mCdkl5_7 2796 931 - - mCdkl5_2–21 Δ17s19Δ20
- mCdkl5_8 2817 938 CDKL5105 Cdkl5-001 mCdkl5_2–22 Δ17s19Δ20Δ21
The new proposed nomenclature system, former names, equivalent Ensembl transcript model and coding region sizes. The descriptive name indicates, in
addition to the major coding isoform, the variable exon usage associated with each transcript: Δ indicates that an exon is not used; s indicates that the
short form of the exon is used, where an alternative splice site is present.
doi:10.1371/journal.pone.0157758.t003
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transcripts terminating at exon 19 in human, where some transcripts use a more distal polyade-
nylation signal, resulting in a larger 3’-UTR and a longer transcript (~12.8 kb). To distinguish
the extra-long (and less abundant) ~12.8 kb transcripts from the abundant 9.7kb transcripts, a
subscripted ‘XL’ symbol at the end of the name signifies usage of the distal polyadenylation sig-
nal and inclusion of the extra-long 3’UTR i.e. hCDKL5_1XL (Table 1).
Expression of CDKL5/Cdkl5 during Development
Mutations in CDKL5 have neurodevelopmental consequences and therefore we wished to
assess the expression of CDKL5 transcripts during pre- and perinatal brain development. An
analysis of CDKL5 expression in the human brain during pre- and post-development was car-
ried out using qRT-PCR and semi-quantitative end-point RT-PCR on a total RNA sample iso-
lated from foetal brain and compared to the expression in adult whole brain. The CNS
isoforms, hCDKL5_1, _2, _3 and _4, are all expressed at higher levels in the adult brain than in
the foetal brain, especially hCDKL5_2 and 4 (Fig 7). Isoform hCDKL5_5, which is expressed
only in the testis in the adult (Fig 2) is, however, expressed in the foetal brain (Fig 7D and 7E).
The expression of Cdkl5 across a developmental time series in mouse was also investigated.
Total RNA was isolated from the brains of mouse embryos at embryonic day 13, 17 and 20,
Fig 7. CDKL5 expression levels during development. End-point (A) and quantitative RT-PCR analysis (B-D) of CDKL5 transcript isoforms
in total RNA isolated from human foetal and adult brain. Expression levels in each assay are shown relative the adult brain sample. (E)
Comparative expression levels of human transcripts as revealed by 2-ΔCt analysis are shown, where all values are relative to the hCDKL5_1 +
_3 assay of the adult brain. All qRT-PCR assays were normalised to β-Actin endogenous controls and are shown as dot plots; bars indicate
the standard error of the mean. It was not possible to discriminate between hCDKL5_1 and hCDKL5_3, or hCDKL5_2 and hCDKL5_4
transcripts, due to qRT-PCR design constraints and therefore these results show the cumulative expression of both isoforms.
doi:10.1371/journal.pone.0157758.g007
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and postnatal days 1, 7, 24 and 45 (n = 3 at each time-point). RT-PCR and qRT-PCR analysis
showed thatmCdkl5_1 andmCdkl5_2 are expressed throughout embryonic and early postnatal
development, increasing in levels and peaking within the first few weeks after birth, with
mCdkl5_2 being expressed at lower levels thanmCdkl5_1 (Fig 8). Of the two isoforms
expressed predominantly in the adult mouse testis,mCdkl5_6 was undetectable in the brain at
Fig 8. Cdkl5 expression levels during development. (A-E) End-point and quantitative RT-PCR analysis of Cdkl5 transcript isoforms in total RNA
isolated frommouse whole brains at different times of embryonic (E13-E20) and postnatal (P1–P45) development. Three animals were analysed at each
time-point; one representative sample from each time-point is shown on the gel image. Expression levels in each assay are shown relative the P45
sample. (F) β-actin loading control. (G) Comparative expression levels of the mouse qRT-PCR assays using 2-ΔCt analysis are shown, where all values
are relative to themCdkl5_1 assay of the P45 adult brain. All qRT-PCR assays were normalised to β-Actin endogenous controls and are shown as dot
plots; bars indicate the standard error of the mean.
doi:10.1371/journal.pone.0157758.g008
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any time-point andmCdkl5_7 was detected only at very low levels in the P7, P24 and P45 brain
(Fig 8C and 8D).mCdkl5_8, which is expressed at low levels in the adult mouse brain, is
expressed throughout development, showing maximal expression at late embryonic stages E17
and E20 and decreasing thereafter to adulthood (Fig 7E). In terms of relative abundance, a
comparison across transcripts revealed pronounced differences in expression profiles over time
(Figs 7E & 8G, for human and mouse respectively).
Discussion
CDKL5 disorder is a rare, debilitating form of early infantile epileptic encephalopathy and
severe intellectual disability caused by a range of de novomutations in the CDKL5 gene. Under-
standing how these mutations affect CDKL5 function requires a detailed knowledge of the
gene structure and isoform expression. Using a combination of bioinformatic analyses and
molecular methods we extend previous descriptions of the gene structure of CDKL5 [5, 24, 25,
32, 33] to provide a detailed characterisation of the human and mouse CDKL5 transcript sets,
permitting a detailed cross-species comparison. We have confirmed previous findings that
hCDKL5_1 (formerly CDKL5107) is the predominant brain isoform of CDKL5. hCDKL5_1 is a
9.7 kb transcript comprised of 18 exons and a large 6.6 kb 3’-UTR. However, we now demon-
strate considerably greater diversity in human and mouse CDLK5 transcripts than previously
realised. This diversity arises from alternative promoter and first exon usage and from alterna-
tive splicing, and these patterns are in many cases species-specific.
Cross-Species Comparison in CDKL5 Isoform Expression
We identified all splicing events that occur across a diverse panel of tissues and validated these
by Sanger sequencing of RT-PCR products spanning multiple exons. This thereby elucidated
even rare splice variants in both mouse and human brain tissue. The majority of the CDKL5
coding region is orthologous and well-conserved between human and mouse (Fig 9). There
are, however, exonic regions towards the 5’ end and 3’ end of each gene that show less conser-
vation (29–42% sequence identity across the equivalent genomic DNA sequence) and are
involved in the generation of alternative transcripts and several different CDKL5/Cdkl5 C-ter-
minal regions. In total, five different coding transcript isoforms in human CDKL5 and five in
mouse Cdkl5 were characterised. However, only the two isoforms expressed most abundantly
in the CNS, hCDKL5_1/mCdkl5_1 and hCDKL5_2/mCdkl5_2, were found to be completely
orthologous (Table 3).
Our results confirm that hCDKL5_1 (formerly CDKL5107) is the most abundant transcript
isoform in the CNS for both mouse and human [25]. This isoform was detected in all other tis-
sues tested, but at lower levels. Previous northern blot data had suggested that very large
CDKL5/Cdkl5 transcripts were expressed in human and mouse brains, and that a different,
smaller transcript is expressed in human and mouse testes [24]. However, this preliminary
Fig 9. Comparison of humanCDKL5 andmouseCdkl5 gene structures.
doi:10.1371/journal.pone.0157758.g009
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observation had not been followed up in subsequent studies. Our characterisation of CDKL5
UTRs confirms that, in adults, large transcripts of ~9.7 and ~12.8 kb in human, and ~9.7 kb in
mouse, are predominantly expressed in the CNS; and that transcripts of ~3.4 kb in human and
~3.2 kb in mouse are almost exclusively expressed in the testis.
In addition to identifying this variation, we looked for evidence confirming the existence of
theoretical transcripts hCDKL5115+ex.16b and hCDKL5-ex.19m predicted by previous studies [17],
but found none. Although the full significance of this transcript diversity is unclear, it is appar-
ent that the putative catalytic domain of CDKL5 is preserved across all isoforms and this corre-
sponds to a region within which most pathogenic missense mutations occur [17, 29]. The
species-specific diversity identified occurs within regulatory regions (5’ and 3’) and at the very
end of the C-terminal domain of CDKL5. This correlates with regions of the gene that show
the lowest degree of homology, suggesting that the observed alternative splicing may be impor-
tant in regulating expression and function. Variation in regions outside the catalytic domain
(exons 17 and part of exon 11) is also seen (Fig 1, S3 Fig). Exon 17 is present in transcripts
hCDKL5_2 and hCDKL5_4 and its inclusion adds 41 amino acids to the protein. This exon is
extremely well conserved between human and mouse, but we can find no evidence of it con-
taining known functional elements. Use of the cryptic splice site in exon 11 (hCDKL5_3 and
hCDKL5_4) results in the loss of 17 amino acids, a region that contains a putative nuclear loca-
lisation signal [43], suggesting that human isoforms utilising this splice site may lead to altered
ratios of CDKL5 protein in different cellular compartments. The functional relevance of these
isoforms is at present unknown, but, in terms of expression levels, they account for less than
10% of CDKL5 transcripts expressed in whole brain (Fig 7, S3 Fig).
It will be important to examine CDKL5/CDKL5 expression in human tissue to determine
whether human-specific isoforms show restricted spatial and temporal expression profiles, as
this may yield insights into the targeting of mRNA/protein to discrete cellular compartments.
However, currently, the lack of effective antibodies against CDKL5 has hampered efforts to
fully characterise the various protein isoforms.
CDKL5 Complexity: Promoters, TSSs and UTRs
As discussed above, diversity between species was particularly prominent in alternative pro-
moter and first exon usage. The 5’-UTR shows far greater complexity in humans than in
mouse. Little is known about transcriptional regulation of CDKL5 and its various putative pro-
moter regions remain poorly defined. In a recent study by the FANTOM5 project, CDKL5 was
predicted to contain a TATA-less promoter lying within a CpG island, in a region immediately
upstream of exon 1 [44]. The major TSS in both human and mouse mapped to the same nucle-
otide in our 5’-RACE analysis, in agreement with the DataBase of Transcriptional Start Sites
[45]. A number of other TSSs were found to cluster close by, but not in a ‘broad’ distribution as
expected for genes with a CpG islands (Fig 3A) [46]. This ‘intermediate’-type promoter may
have consequences for the regulation of CDKL5 expression, potentially via downstream tran-
scription-associated chromatin organisation [47]. We have identified multiple first exons and
we therefore predict that four further promoters lying between exons 1 and 2 should exist. Fur-
ther studies are required to characterise these additional promoters.
The identification of large 3’-UTRs (> 6.6 kb) in the major brain isoforms may suggest
additional, previously unrecognised, modes of regulation of CDKL5.mCdkl5mRNA has been
reported to be present in dendrites in the adult brain where it may have a role in local Cdkl5
synthesis [18]. It is possible that these large 3’-UTRs may have a role in trafficking Cdkl5 to the
dendrites, and it is noticeable that there is a high degree of sequence conservation within this
region (Fig 9). However, an analysis of the potential role of large conserved UTRs in mRNA
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trafficking within neurons requires further investigation. A number of putative miRNA bind-
ing sites in the 3’-UTR have already been recognised [48, 49], but the importance of this mode
of regulation is not clearly established for CDKL5, as a review of recent studies suggested that
CDKL5 protein levels tend to correlate with mRNA expression levels in the adult brain [17].
Temporal and Spatial Diversity of CDKL5
Our analysis of CDKL5/Cdkl5 expression reveals a dynamic regulation of individual transcript
levels during neurodevelopment. Indeed we find that transcriptsmCdkl5_8 and hCDKL5_5,
previously believed to be testis-specific, are expressed in the brain during development. This
finding is of particular significance since mutations in exons 20–22 have hitherto been classi-
fied as being non-pathogenic [50]. More generally, in the mouse brain, Cdkl5 protein expres-
sion has been reported to be at low levels during early developmental stages (E16.5), and then
strongly induced during early postnatal stages [12]. Our results show examples of transcripts
whose expression levels change in a more graded fashion over extended periods of develop-
ment; for example,mCdkl5_1 increases from E17-P24, whereasmCdkl5_8 shows a gradual
decrease over the same period. The detection of different transcript isoforms is suggestive of
complex developmental regulation of CDKL5 expression patterns and levels during pre- and
postnatal development. However, the functional significance of different CDKL5 transcript iso-
forms and whether there are levels of redundancy across CDKL5 transcripts remains to be
assessed.
Nomenclature
To accompany the analysis of human CDKL5 and mouse Cdkl5 transcript isoforms a new stan-
dardised nomenclature system is proposed. In addition to the former names described in
Table 3, designations such as ‘isoform I’ and ‘isoform II’ have also been used, and the number
of alternative designations for the same entity has been an obstacle to consistent CDKL5 termi-
nology. The new proposed nomenclature system retains flexibility and takes into account the
complexity of transcript isoforms characterised in this study, providing a reference for future
work on this gene.
Overall, the complexity of CDKL5 transcripts highlighted in this study needs to be taken
into account when developing gene-based, protein-based or pharmacotherapies for CDKL5
disorders. The data may also aid the development of isoform-specific antibodies. The complex-
ity and dynamic regulation of CDKL5 may also be important when considering the time-
course of CDKL5 disorder pathophysiology and potential time-points for therapeutic interven-
tion. The detailed characterisation of CDKL5/Cdkl5 should not only inform the design of
CDKL5mutation screening assays but, importantly, also provide a valuable platform for funda-
mental research into the biology of CDKL5.
Supporting Information
S1 Fig. Primer locations and sequences. PCR Primer pairs specific for each isoform in (A)
human and (B) mouse are listed, and the diagrams indicate the coverage of the resultant ampli-
cons. (C) The primer pair designed to amplify hCDKL5_1 will also amplify hCDKL5_5, if
hCDKL5_5 is expressed in that tissue. As hCDKL5_5 is expressed primarily in the adult testis,
the assay is therefore quite specific for hCDKL5_1. An alternative primer pair that amplifies
hCDKL5_1 + _3 simultaneously was tested in the panel of adult tissues and a similar pattern of
expression observed.
(TIF)
CDKL5 Transcript Isoforms in Human and Mouse
PLOS ONE | DOI:10.1371/journal.pone.0157758 June 17, 2016 18 / 22
S2 Fig. CDKL5 isoform expression in human tissues. RT-PCR analysis of CDKL5 transcript
isoforms in a panel of adult tissues. GAPDH was used as a loading control.
(TIF)
S3 Fig. Alternative splicing affecting human CDKL5 and mouse Cdkl5 coding regions.
RNA-seq data from brain (red) and testis (blue) datasets show reads mapping to (A) exons 16,
17 and 18 in human and mouse and (B) exons 10, 11 and 12 in human. In both diagrams the
number on the y-axis indicates maximum read count and the dotted lines between splice
donor and acceptor sites indicate the number of reads that map to that exon-exon junction. All
reads contributing to these data span a maximum of two exons. (C) RT-PCR of total RNA iso-
lated from brain tissue in human and mouse. Products confirming the presence of exon 17 in
CDKL5 and Cdkl5 transcripts were gel-purified and sequenced (the 285 bp band in the left gel
image). A low abundance product confirming the use of an alternative splice site in exon 11 in
CDKL5 transcripts was gel-purified and sequenced (the 146 bp band in the right gel image).
(D,E) Sequence of PCR amplicons in (C). Primers are indicated by red arrows. The 3’ end of
exon 11 in human and mouse, showing the presence of a cryptic splice site in human and its
absence in mouse due to a single nucleotide difference (highlighted in red).
(TIF)
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